Christopher Freeburn

Christopher Freeburn

InvestorPlace Writer

Christopher T. Freeburn has been a financial writer and editor for more than 10 years. He has worked at industry trade publications like Food Logistics, ChemicalWeek and Institutional Investor. His freelance articles have appeared in a variety of magazines, including Technology Review, Audubon and USA Weekend. He lives in Westchester County, just outside New York City.”

Recent Articles

CYTK: Cytokinetics Stock in Ugly Free Fall on ALS Drug Fail

By Christopher Freeburn, InvestorPlace Writer

Cytokinetics stock plunged 60% after CYTK revealed that its amyotrophic lateral sclerosis drug hadn't met the primary goal of a mid-stage clinical trial.

SNV: Synovus Stock Falls on 1:7 Reverse Stock Split News

By Christopher Freeburn, InvestorPlace Writer

Synovus Financial Corporation announced a one-for-seven reverse stock split for its common stock in May. SNV stock sank on the news.

ABBV: AbbVie Beats Street on Soaring Humira Sales

By Christopher Freeburn, InvestorPlace Writer

Pharmaceutical-maker AbbVie posted first-quarter sales that beat estimates on surging sales of its Humira drug, sending ABBV stock higher.

UA, BEAM: Under Armour to Replace Beam in S&P 500

By Christopher Freeburn, InvestorPlace Writer

Under Armour will join the S&P 500 on April 30, replacing Beam, which is being acquired by Suntory. UA stock rose on the news.

Gold and Silver Report: AUY Sinks After GG Drops Hostile Osisko Bid

By Christopher Freeburn, InvestorPlace Writer

Gold rose for a second session on increasing tensions in Ukraine. AUY shares fell after GG abandoned its hostile bid for Osisko Mining.

Load More